CEP-11981
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- CEP-11981
- Molecular weight
- 477.57
- Structure (SMILES)
- CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
- bol 303213x
- BOL-303213X
- cep 11981
- Cep 11981
- CEP 11981 [WHO-DD]
- cep 11981 kinase inhibitor
- cep 11981 who dd
- Cep-11981
- CEP-11981
- CEP-11981 (kinase inhibitor)
- cep11981
- CEP11981
- CAS registry numbers
- 856691-93-5
- ChEMBL ID
- CHEMBL2010872
- InChIKey
- AEULIVPVIDOLIN-UHFFFAOYSA-N
- PubChem compound IDs
- 11751922
- FDA ingredient codes (UNII)
- J8AY0Z4CBP
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- CEP-11981
- Type
- Synthetic organic
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- mitogen-activated protein kinase kinase kinase 7
- Gene symbol
- MAP3K7
- Protein identifier
- O43318
- Median affinity
- 7.85
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- neurotrophic receptor tyrosine kinase 1
- Gene symbol
- NTRK1
- Protein identifier
- P04629
- Median affinity
- 8.52
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- ret proto-oncogene
- Gene symbol
- RET
- Protein identifier
- P07949
- Median affinity
- 8.3
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- fibroblast growth factor receptor 1
- Gene symbol
- FGFR1
- Protein identifier
- P11362
- Median affinity
- 7.89
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- fms related receptor tyrosine kinase 1
- Gene symbol
- FLT1
- Protein identifier
- P17948
- Median affinity
- 8.52
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- kinase insert domain receptor
- Gene symbol
- KDR
- Protein identifier
- P35968
- Median affinity
- 8.4
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- BLK proto-oncogene, Src family tyrosine kinase
- Gene symbol
- BLK
- Protein identifier
- P51451
- Median affinity
- 8.1
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- TEK receptor tyrosine kinase
- Gene symbol
- TEK
- Protein identifier
- Q02763
- Median affinity
- 7.59
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- serine/threonine kinase 3
- Gene symbol
- STK3
- Protein identifier
- Q13188
- Median affinity
- 7.68
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- neurotrophic receptor tyrosine kinase 2
- Gene symbol
- NTRK2
- Protein identifier
- Q16620
- Median affinity
- 8.3
- Affinity units
- pIC50
- Mechanism
- Tyrosine-protein kinase TIE-2 inhibitor
- Action type
- Inhibitor
- Target
- Angiopoietin-1 receptor
- Protein identifier
- Q02763
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Vascular endothelial growth factor receptor
- Protein identifier
- P17948
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Vascular endothelial growth factor receptor
- Protein identifier
- P35916
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Vascular endothelial growth factor receptor
- Protein identifier
- P35968
- Mechanism
- Tyrosine-protein kinase TIE-2 inhibitor
- Action type
- Inhibitor
- Target
- Angiopoietin-1 receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Vascular endothelial growth factor receptor
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 2
- NCT00875264
- NCT04159896
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 2
- Polar surface area
- 89.66
- Calculated partition coefficient (ALogP)
- 4.73
- Calculated partition coefficient (XLogP)
- 3.9
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 36
- Molecular formula
- C28H27N7O
- Monoisotopic mass
- 477.22770851
- Natural product
- No
- Recorded assays
- 154
- Active assays
- 59
- Confirmatory
- Other
These details could not be displayed.
Related records
Trials (16)
- A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma
- A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt
- Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors
- Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
- AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies
- Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer
- Identification of PAthways of Kinase Inhibitors TOxicity
- Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
- KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
- Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer
- Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
- Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
- Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)
- Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
- VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
In development for (2)
- Cancer Phase 1
- Metastatic prostate carcinoma Phase 2